about
The value of polyurethane-cuffed endotracheal tubes to reduce microaspiration and intubation-related pneumonia: a systematic review of laboratory and clinical studiesSpectrum of practice in the diagnosis of nosocomial pneumonia in patients requiring mechanical ventilation in European intensive care unitsCumulative Evidence of Randomized Controlled and Observational Studies on Catheter-Related Infection Risk of Central Venous Catheter Insertion Site in ICU Patients: A Pairwise and Network Meta-Analysis.Does contemporary vancomycin dosing achieve therapeutic targets in a heterogeneous clinical cohort of critically ill patients? Data from the multinational DALI study.Pharmacokinetic variability and exposures of fluconazole, anidulafungin, and caspofungin in intensive care unit patients: Data from multinational Defining Antibiotic Levels in Intensive care unit (DALI) patients Study.Characteristics and risk factors for 28-day mortality of hospital acquired fungemias in ICUs: data from the EUROBACT studyDiagnosis and management of temperature abnormality in ICUs: a EUROBACT investigators' survey.DALI: Defining Antibiotic Levels in Intensive care unit patients: a multi-centre point of prevalence study to determine whether contemporary antibiotic dosing for critically ill patients is therapeutic.Population Pharmacokinetics of Fosfomycin in Critically Ill Patients.Quality of life outcome of critical care survivors eighteen months after discharge from intensive careGram-negative bacterial pneumonia: aetiology and management.Hospital-acquired pneumonia in the 21st century: a review of existing treatment options and their impact on patient care.What is the relevance of fosfomycin pharmacokinetics in the treatment of serious infections in critically ill patients? A systematic review.Approach to invasive pulmonary aspergillosis in critically ill patients.Respiratory infections in patients undergoing mechanical ventilation.Nosocomial pneumonia in 27 ICUs in Europe: perspectives from the EU-VAP/CAP study.Is prolonged infusion of piperacillin/tazobactam and meropenem in critically ill patients associated with improved pharmacokinetic/pharmacodynamic and patient outcomes? An observation from the Defining Antibiotic Levels in Intensive care unit patienCOPD patients with ventilator-associated pneumonia: implications for management.The Surviving Sepsis Campaign bundles and outcome: results from the International Multicentre Prevalence Study on Sepsis (the IMPreSS study).Angiopoietin-2 associations with the underlying infection and sepsis severity.Point prevalence of surgical checklist use in Europe: relationship with hospital mortality.Potentially resistant microorganisms in intubated patients with hospital-acquired pneumonia: the interaction of ecology, shock and risk factors.Evaluating rates of ventilator-associated pneumonia: Consider patient, organizational & educational risk factors.Patient to nurse ratio and risk of ventilator-associated pneumonia in critically ill patients.Nebulization of antimicrobial agents in mechanically ventilated adults in 2017: an international cross-sectional survey.Optimizing educational initiatives to prevent ventilator-associated complications.Risk factors for target non-attainment during empirical treatment with β-lactam antibiotics in critically ill patients.Reply to Rhodes et al.Variability in protein binding of teicoplanin and achievement of therapeutic drug monitoring targets in critically ill patients: lessons from the DALI Study.Prevalence, risk factors, and mortality for ventilator-associated pneumonia in middle-aged, old, and very old critically ill patients*.Erratum to: Risk factors for target non-attainment during empirical treatment with β-lactam antibiotics in critically ill patients.Critically ill elderly adults with infection: analysis of the extended prevalence of infection in intensive care study.Characteristics and determinants of outcome of hospital-acquired bloodstream infections in intensive care units: the EUROBACT International Cohort Study.The authors replyRisk factorsDeterminants of prescription and choice of empirical therapy for hospital-acquired and ventilator-associated pneumoniaOral care practices in intensive care units: a survey of 59 European ICUsInfections by multidrug-resistant Gram-negative Bacteria: What's new in our arsenal and what's in the pipeline?Candida burn wound sepsis: The “holy trinity” of managementThe authors reply
P50
Q27339247-EA05F02D-B30D-4BC7-B1B1-A310601AABACQ28248724-55079F5A-216E-444D-BBE7-D6381B6DB259Q30245340-6FEF773A-3F7C-4FFD-97D0-19BEFBFFCF36Q30828312-4F62728B-4375-4C5C-B6E7-30977C9A4A94Q30936281-A1455C1E-7315-448C-8DAA-921FB6AC6DB2Q31054881-CDD7A8C1-4684-414E-AFDB-640E0EB5F6F1Q33754287-807AB590-6582-432F-9B16-E7318127D364Q34329290-B624D0C5-8A0E-4940-8747-F97A5D487CA9Q36075930-BEC1B6DA-2E17-469B-9828-BC6C3E9B9CF0Q36405282-076EEF9E-DE2D-4227-82C5-447E13A05FE9Q36438624-52059EE8-9754-4834-885A-8AAAB0F67412Q36548708-C582EF43-C230-4460-9D97-F913625EAB5BQ38123590-5AAFA943-60CC-481F-AE21-2317EB94BF51Q38186970-F05C5820-E5AF-456C-91B3-D66B637A4318Q38242626-D4919D4A-4D04-480A-99CD-18AD2C28D286Q38861673-DB063B4F-C33B-465B-9CF0-29FB33885DB6Q40470332-0A6F6156-FBD9-48F7-82DE-8AC694C9FEF5Q40500207-59AACFB5-D155-4F25-A3D8-4C9BCF7B3C72Q41141313-B72BEAD7-86EC-4E70-AFD7-78C31E8809C1Q41444491-193308B3-4067-41ED-AEBD-F592465803D4Q41585540-F36E3932-3A89-4B47-BEC8-01F6DCAC7DCCQ42277212-C102A683-A7E7-4BD9-9D19-C5BE2BCDDBE0Q42689520-AB7E60F0-8D4C-480A-B223-B7FC55C492E3Q46012265-8CE608A2-87B8-4788-A653-390D523B3313Q47213441-3BB16FAC-96D0-4346-AB83-C2180E49CA3DQ48028360-DC1F6424-2816-4132-BFE5-054D1EA3FAC5Q49056677-C8AE9AD4-BE44-49E2-B482-5B42375A64D1Q49067719-B2684631-351C-4754-869E-9CDE105D1C86Q49082780-3780E749-7184-438D-809C-8F6FE08696E1Q49108169-57BE3F01-F6DF-47BA-8C2C-C07B3F4305CFQ49150727-FAE49C8C-DFD7-461D-B4A9-D4154544BACCQ53095895-3F5E06F8-C0BA-4C97-A0A2-769BC2101EE2Q53123244-5E50857C-E8EA-4E0E-A142-9D92BEAEAB1EQ57237703-7AB96450-44D5-4C60-9B8A-B4B6EBA269C8Q57237748-858CF35A-E5E0-4F97-82A0-9A17DB2E4E24Q57237793-40DB7CA6-B7A1-4AC2-B22B-7F3BFB254CDAQ57237934-BEFC7F61-0E84-41A3-B57F-9AA72B5BFF06Q64131412-636C3BA2-6AD9-433C-BDAC-CDB7414C328AQ64131416-D783333E-D10F-44B9-8BC4-B7E81AA9AE94Q64131423-9A959D45-0515-4813-B030-E7F99A5E57D3
P50
description
hulumtuese
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Despoina Koulenti
@ast
Despoina Koulenti
@en
Despoina Koulenti
@es
Despoina Koulenti
@nl
type
label
Despoina Koulenti
@ast
Despoina Koulenti
@en
Despoina Koulenti
@es
Despoina Koulenti
@nl
prefLabel
Despoina Koulenti
@ast
Despoina Koulenti
@en
Despoina Koulenti
@es
Despoina Koulenti
@nl
P106
P1153
14012112900
P21
P31
P496
0000-0003-4364-2612